Performance in Delivering Qtr 2 2021-22

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
55180	20/EM/0049	273949	M19-944: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis	Number Agreed	2	2	Date Agreed	20/05/2021	2	20/05/2021	0	Recruitment Finished	No eligible patients
< Back 55181	19/ES/0100	261027	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)	Number Agreed	0	2	Date Agreed	31/01/2021	2	05/01/2021	2	Recruitment Finished	
55182	18/NE/0023	230930	Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults	Number Agreed	5	5	Date Agreed	31/03/2021	4	21/04/2021	4	Recruitment Finished	A number of patients failed screening